ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease.
… event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline … for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the … a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce …
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”
… call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently … About Axiomer ® ProQR is pioneering a next-generation RNA editing technology called Axiomer ® , which could … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change …
… October 21, 2025 Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 … October 21, 2025 Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 …
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.